Videos

Jason M. Goldman, MD, MACP, discusses the potentially damaging effects of the rhetoric coming from the presidential executive order including downstream consequences as well as his concerns around the prospective findings of the HHS Task Force on Safer Childhood Vaccines associated with it.

The EU recently approved glecaprevir/pibrentasvir (Maviret), an eight-week direct-acting antiviral regimen, which offers people with hepatitis C the fastest treatment option available, giving European health systems a new tool in aiding the World Health Organization's goal of eliminating the virus by 2030.

The European Commission has approved glecaprevir/pibrentasvir (Maviret) for acute hepatitis C virus (HCV) infection, making it the only therapy approved in the European Union for both acute and chronic HCV and allowing clinicians to test and treat patients at the point of diagnosis. Mudra Kapoor, MD, discusses the phase 3 data and the treatment's potential role for greater HCV elimination.

Although there has been conflicting public information around whether the source of the outbreak has been determined, Catherine O’Neal, MD, offers insights on key symptoms that warrant medical evaluation, what medical treatment may consist of for those being seen in an outpatient setting or those who are hospitalized, and considerations around eating produce.

From the early days with no treatment, to AZT providing a lifeline, to today’s generation of antiretroviral therapies (ART), Perry N. Halkitis, PhD, MS, MPH, reminds people of how they have transformed the lives of people with HIV.

Kartik Cherabuddi, MD, FACP, FIDSA, provides insights on these aspects of the parasitic infection.

New research from Rutgers University suggests that bacterial responses to antibiotics vary significantly under nutrient-limited conditions, highlighting potential limitations of standard laboratory susceptibility testing and offering new insights into why some laboratory findings fail to predict clinical outcomes.

Accurate, rapid diagnostics capable of distinguishing Ebola from other febrile illnesses are essential to controlling the ongoing, Bundibugyo Ebola outbreak. bioMérieux is deploying its Global Fever Special Pathogens Panel to affected regions in partnership with local governments. Chuck Cooper, MD, chief medical officer at bioMérieux, offers some insights on this testing platform and the importance of coordination with African countries to secure and deliver this technology to the hot zones and beyond.

DOTS data on dalbavancin for complicated S aureus bacteremia and PETERPEN interim results for ESβL bloodstream infections provide potential options to revisit first-line therapy. Megan Klatt, PharmD, BCIDP, DPLA, discusses insights from these trials and how they can affect clinical practice and stewardship.

Preclinical findings demonstrate that the novel efflux pump inhibitor TXA14007 significantly enhances azithromycin activity against multidrug-resistant Gram-negative bacteria, supporting a potential new oral treatment strategy for difficult-to-treat infections. Jesus Rosado-Lugo, PhD, offers insights on the study at ASM Microbe 2026.

Why ceftobiprole gains traction: infusion data and lab susceptibility reports help clinicians tackle stubborn Staph aureus bacteremia.

While Americans are being affected by Ebola and Hantavirus, the federal government has made concerted efforts to decrease biopreparedness programs, including reducing funding, and downsizing personnel who study and address high-consequence infectious diseases (HCID). Despite these efforts, the US has had protocols, infrastructure, and medical personnel in place to deal with these current situations.

ERADICATE trial data show ceftobiprole is well-tolerated with mostly mild GI effects and no emerging resistance versus daptomycin.

The American Society for Microbiology (ASM) is leveraging its new phage therapy coordination efforts to connect researchers and clinicians, standardize approaches, and explore how bacteriophages could complement antibiotics in the fight against antimicrobial resistance. Colleen Kraft, MD, offers some insights on the organization's plans to help grow this medical modality.

A new multiplex blood-screening assay is streamlining transfusion safety by enabling simultaneous detection and discrimination of HIV, HBV, HCV, and hepatitis E in a single test, helping laboratories improve efficiency, reduce turnaround times, and strengthen blood supply resilience amid ongoing donation and staffing shortages. Nico Michel, PhD, of Roche Diagnostics, offers insights on this diagnostic.

A novel antimicrobial susceptibility testing platform, ATB Finder, is designed to improve treatment outcomes by evaluating antibiotics under conditions that closely mirror the infection site and microbial communities found in patients. George Tetz, MD, PhD, offers insights on this platform.

The FDA's accelerated approval of this therapy provides the first approved treatment option for chronic hepatitis delta in the US. Anu Osinusi, MD, discusses how this targeted therapy is designed to slow disease progression and improve patient outcomes.

Kelly Oakeson, PhD, explains how Utah public health officials are leveraging a statewide wastewater surveillance system to monitor measles activity, identify emerging outbreaks, and supplement traditional case reporting.

FDA- and EMA-approved ceftobiprole matches daptomycin outcomes, offering a new beta-lactam option for MRSA bloodstream infections.

Inside the ERADICATE study: ceftobiprole matches daptomycin for complicated MRSA/MSSA bloodstream infections, expanding treatment options.

In the second episode with Emory’s Gavin Harris, MD, he offers some insights about treating patients with the Andes virus, including supportive care as well as investigational antivirals.

Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.

At the MAD-ID and SIDP 2026 annual meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.

Emory’s Gavin Harris, MD, discusses how getting patients this type of treatment is essential to reducing the severity of disease, as well as adapting the four “I’s” algorithm in dealing with high-consequence infectious disease outbreaks.

In the second episode of our conversation with David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, he discusses the person-to person transmission, if we expect to see more cases and how it presents, including a serious complication of the virus.

Staph aureus bloodstream infections remain deadly worldwide; vancomycin and daptomycin anchor MRSA bacteremia care, but dosing complexity, toxicity, and resistance persist.

David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, provides information on this strain, the quarantine protocols, and what the public should know about when the virus sheds and transmissibility of the disease to others.

People with substance use disorder (SUD) face a disproportionate burden of hepatitis infections, underscoring the importance of testing, vaccination, and access to curative treatment during Viral Hepatitis Awareness Month. Stephanie Spivack, MD, offers some insights on the disease burden for this patient population as well as the challenging aspects of getting them into care.